Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Granulomatosis with Polyangiitis Drug Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Granulomatosis with Polyangiitis Drug Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Benralizumab
      • 1.3.3 Avacopan
      • 1.3.4 Rituximab Biosimilar
      • 1.3.5 Others
    • 1.4 Market Segment by Application
      • 1.4.1 Global Granulomatosis with Polyangiitis Drug Market Share by Application (2019-2025)
      • 1.4.2 Hospital
      • 1.4.3 Clinic
      • 1.4.4 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Granulomatosis with Polyangiitis Drug Market Size
      • 2.1.1 Global Granulomatosis with Polyangiitis Drug Revenue 2014-2025
      • 2.1.2 Global Granulomatosis with Polyangiitis Drug Sales 2014-2025
    • 2.2 Granulomatosis with Polyangiitis Drug Growth Rate by Regions
      • 2.2.1 Global Granulomatosis with Polyangiitis Drug Sales by Regions 2014-2019
      • 2.2.2 Global Granulomatosis with Polyangiitis Drug Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Granulomatosis with Polyangiitis Drug Sales by Manufacturers
      • 3.1.1 Granulomatosis with Polyangiitis Drug Sales by Manufacturers 2014-2019
      • 3.1.2 Granulomatosis with Polyangiitis Drug Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Granulomatosis with Polyangiitis Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Granulomatosis with Polyangiitis Drug Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Granulomatosis with Polyangiitis Drug Market Concentration Ratio (CR5 and HHI)
    • 3.3 Granulomatosis with Polyangiitis Drug Price by Manufacturers
    • 3.4 Key Manufacturers Granulomatosis with Polyangiitis Drug Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Granulomatosis with Polyangiitis Drug Market
    • 3.6 Key Manufacturers Granulomatosis with Polyangiitis Drug Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Benralizumab Sales and Revenue (2014-2019)
      • 4.1.2 Avacopan Sales and Revenue (2014-2019)
      • 4.1.3 Rituximab Biosimilar Sales and Revenue (2014-2019)
      • 4.1.4 Others Sales and Revenue (2014-2019)
    • 4.2 Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type
    • 4.3 Global Granulomatosis with Polyangiitis Drug Revenue Market Share by Type
    • 4.4 Granulomatosis with Polyangiitis Drug Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Granulomatosis with Polyangiitis Drug Sales by Application

    6 United States

    • 6.1 United States Granulomatosis with Polyangiitis Drug Breakdown Data by Company
    • 6.2 United States Granulomatosis with Polyangiitis Drug Breakdown Data by Type
    • 6.3 United States Granulomatosis with Polyangiitis Drug Breakdown Data by Application

    7 European Union

    • 7.1 European Union Granulomatosis with Polyangiitis Drug Breakdown Data by Company
    • 7.2 European Union Granulomatosis with Polyangiitis Drug Breakdown Data by Type
    • 7.3 European Union Granulomatosis with Polyangiitis Drug Breakdown Data by Application

    8 China

    • 8.1 China Granulomatosis with Polyangiitis Drug Breakdown Data by Company
    • 8.2 China Granulomatosis with Polyangiitis Drug Breakdown Data by Type
    • 8.3 China Granulomatosis with Polyangiitis Drug Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Granulomatosis with Polyangiitis Drug Breakdown Data by Company
    • 9.2 Rest of World Granulomatosis with Polyangiitis Drug Breakdown Data by Type
    • 9.3 Rest of World Granulomatosis with Polyangiitis Drug Breakdown Data by Application
    • 9.4 Rest of World Granulomatosis with Polyangiitis Drug Breakdown Data by Countries
      • 9.4.1 Rest of World Granulomatosis with Polyangiitis Drug Sales by Countries
      • 9.4.2 Rest of World Granulomatosis with Polyangiitis Drug Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Bionovis SA
      • 10.1.1 Bionovis SA Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Granulomatosis with Polyangiitis Drug
      • 10.1.4 Granulomatosis with Polyangiitis Drug Product Introduction
      • 10.1.5 Bionovis SA Recent Development
    • 10.2 Bristol-Myers Squibb Company
      • 10.2.1 Bristol-Myers Squibb Company Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Granulomatosis with Polyangiitis Drug
      • 10.2.4 Granulomatosis with Polyangiitis Drug Product Introduction
      • 10.2.5 Bristol-Myers Squibb Company Recent Development
    • 10.3 ChemoCentryx Inc
      • 10.3.1 ChemoCentryx Inc Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Granulomatosis with Polyangiitis Drug
      • 10.3.4 Granulomatosis with Polyangiitis Drug Product Introduction
      • 10.3.5 ChemoCentryx Inc Recent Development
    • 10.4 Coherus BioSciences Inc
      • 10.4.1 Coherus BioSciences Inc Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Granulomatosis with Polyangiitis Drug
      • 10.4.4 Granulomatosis with Polyangiitis Drug Product Introduction
      • 10.4.5 Coherus BioSciences Inc Recent Development
    • 10.5 Genor BioPharma Co Ltd
      • 10.5.1 Genor BioPharma Co Ltd Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Granulomatosis with Polyangiitis Drug
      • 10.5.4 Granulomatosis with Polyangiitis Drug Product Introduction
      • 10.5.5 Genor BioPharma Co Ltd Recent Development
    • 10.6 GlaxoSmithKline Plc
      • 10.6.1 GlaxoSmithKline Plc Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Granulomatosis with Polyangiitis Drug
      • 10.6.4 Granulomatosis with Polyangiitis Drug Product Introduction
      • 10.6.5 GlaxoSmithKline Plc Recent Development
    • 10.7 Iltoo Pharma
      • 10.7.1 Iltoo Pharma Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Granulomatosis with Polyangiitis Drug
      • 10.7.4 Granulomatosis with Polyangiitis Drug Product Introduction
      • 10.7.5 Iltoo Pharma Recent Development
    • 10.8 Panacea Biotec Ltd
      • 10.8.1 Panacea Biotec Ltd Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Granulomatosis with Polyangiitis Drug
      • 10.8.4 Granulomatosis with Polyangiitis Drug Product Introduction
      • 10.8.5 Panacea Biotec Ltd Recent Development
    • 10.9 Sandoz International GmbH
      • 10.9.1 Sandoz International GmbH Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Granulomatosis with Polyangiitis Drug
      • 10.9.4 Granulomatosis with Polyangiitis Drug Product Introduction
      • 10.9.5 Sandoz International GmbH Recent Development
    • 10.10 The International Biotechnology Center (IBC) Generium
      • 10.10.1 The International Biotechnology Center (IBC) Generium Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Granulomatosis with Polyangiitis Drug
      • 10.10.4 Granulomatosis with Polyangiitis Drug Product Introduction
      • 10.10.5 The International Biotechnology Center (IBC) Generium Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Granulomatosis with Polyangiitis Drug Sales Channels
      • 11.2.2 Granulomatosis with Polyangiitis Drug Distributors
    • 11.3 Granulomatosis with Polyangiitis Drug Customers

    12 Market Forecast

    • 12.1 Global Granulomatosis with Polyangiitis Drug Sales and Revenue Forecast 2019-2025
    • 12.2 Global Granulomatosis with Polyangiitis Drug Sales Forecast by Type
    • 12.3 Global Granulomatosis with Polyangiitis Drug Sales Forecast by Application
    • 12.4 Granulomatosis with Polyangiitis Drug Forecast by Regions
      • 12.4.1 Global Granulomatosis with Polyangiitis Drug Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Granulomatosis with Polyangiitis Drug Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of Granulomatosis with Polyangiitis Drug is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Granulomatosis with Polyangiitis Drug.

      This report studies the global market size of Granulomatosis with Polyangiitis Drug, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Granulomatosis with Polyangiitis Drug sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Bionovis SA
      Bristol-Myers Squibb Company
      ChemoCentryx Inc
      Coherus BioSciences Inc
      Genor BioPharma Co Ltd
      GlaxoSmithKline Plc
      Iltoo Pharma
      Panacea Biotec Ltd
      Sandoz International GmbH
      The International Biotechnology Center (IBC) Generium

      Market Segment by Product Type
      Benralizumab
      Avacopan
      Rituximab Biosimilar
      Others

      Market Segment by Application
      Hospital
      Clinic
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Granulomatosis with Polyangiitis Drug status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Granulomatosis with Polyangiitis Drug manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Granulomatosis with Polyangiitis Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now